LBLTF (Lattice Biologics) Shares Buyback Ratio %: 0.00 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lattice Biologics Shares Buyback Ratio %?

Lattice Biologics LBLTF -99.00% Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Lattice Biologics's current shares buyback ratio was 0.00%.

Lattice Biologics Shares Buyback Ratio % Related Terms

Lattice Biologics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics Shares Buyback Ratio % Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,019.10 -47.76 -0.18 0.00 -37.19

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.93 -16.33 0.00 0.00 0.00

Lattice Biologics Shares Buyback Ratio % Calculation

Lattice Biologics's Shares Buyback Ratio for the fiscal year that ended in Sep. 2020 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2019 ) - Shares Outstanding (EOP) (A: Sep. 2020 )) / Shares Outstanding (EOP) (A: Sep. 2019 )
=(93.4583 - 128.2183) / 93.4583
=-37.19%

Lattice Biologics's Shares Buyback Ratio for the quarter that ended in Jun. 2021 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2021 ) - Shares Outstanding (EOP) (A: Jun. 2021 )) / Shares Outstanding (EOP) (A: Mar. 2021 )
=(128.2183 - 128.2183) / 128.2183
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 0.00 mean?
Lattice Biologics (LBLTF) has a Shares Buyback Ratio % of 0.00 as of Sep. 22, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Lattice Biologics and its competitors.
Is Lattice Biologics' Shares Buyback Ratio % too high?
Lattice Biologics' current Shares Buyback Ratio % is 0.00.
How does Lattice Biologics' Shares Buyback Ratio % compare to ABT and MDT?
Lattice Biologics' Shares Buyback Ratio % of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Medical Devices & Instruments company?
A good Shares Buyback Ratio % depends on the Medical Devices & Instruments industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Lattice Biologics and its competitors. Lattice Biologics's current Shares Buyback Ratio % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current Shares Buyback Ratio % of 0.00. The current Shares Buyback Ratio % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current Shares Buyback Ratio % is 0.00 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a regenerative medicine company that develops, manufactures, and markets biologic products derived from human tissue for use in surgical and clinical applications. Its product portfolio includes acellular dermal matrix (ADM) dermis, demineralized bone matrix (DBM) putty, bone scaffold products, and related allografts. These products are used to support bone and tissue repair in applications such as spinal fusion, breast reconstruction following mastectomy, sports medicine, foot and ankle surgery, cranial healing after neurosurgery, and subchondral bone defect repair in knee and other joint procedures. The company sells to hospitals, surgeons, and healthcare providers, generating revenue primarily from product sales in the United States, with additional distribution in international markets. Its operations center on tissue processing and the supply of biologic implants and grafts to the orthopedic, spine, and reconstructive surgery markets.